Betting on Tech
Health Care: Drugs
XOMA Corp (XOMA: NASDAQ)
$3.84 -0.01 | -0.26%
06/18/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 45.34M | 48.34M | 37.30M | 23.91M |
| Receivables | 8.25M | 12.33M | 20.86M | 7.23M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 95.84M | 62.70M | 58.88M | 32.15M |
| Property, Plant & Equipment, Gross | 49.53M | 56.26M | 53.68M | 53.40M |
| Accumulated Depreciation & Depletion | 41.39M | 43.55M | 38.81M | 33.13M |
| Property, Plant & Equipment, Net | 8.14M | 12.71M | 14.87M | 20.27M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.70M | 2.63M | 503.00K | 402.00K |
| Total Non-Current Assets | 9.84M | 15.34M | 15.37M | 20.67M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 105.68M | 78.04M | 74.25M | 52.82M |
| Accounts Payable | 3.87M | 2.13M | 3.58M | 2.94M |
| Short Term Debt | 3.39M | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.54M | 3.18M | 4.25M | 4.98M |
| Total Current Liabilities | 23.83M | 21.01M | 35.53M | 18.68M |
| Long Term Debt | 37.65M | 33.52M | 13.69M | 13.34M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 22.72M | 8.49M | 1.44M | 3.28M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 60.38M | 42.02M | 15.13M | 16.62M |
| Total Liabilities | 84.21M | 63.02M | 50.66M | 35.30M |
| Preferred Stock Equity | 0.00 | 0.00 | 1.00K | 1.00K |
| Common Stock Equity | 21.47M | 15.01M | 23.59M | 17.52M |
| Common Par | 615.00K | 263.00K | 214.00K | 101.00K |
| Additional Paid In Capital | 977.96M | 900.80M | 876.69M | 801.98M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -957.12M | -886.05M | -853.31M | -784.55M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 8.00K | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 59.12M | 48.54M | 37.28M | 30.87M |
| Total Equity | 21.47M | 15.01M | 23.59M | 17.53M |
| Total Liabilities & Stock Equity | 105.68M | 78.04M | 74.25M | 52.82M |
| Total Common Shares Outstanding | 82.45M | 35.11M | 28.49M | 13.54M |
| Preferred Shares | 0.00 | 0.00 | 2.96K | 2.96K |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 64.63M | 31.59M | 18.61M | 10.99M |
| Diluted Weighted Shares Outstanding | 64.63M | 31.59M | 18.61M | 11.31M |
| Number of Employees | 166 | 188 | 230 | 195 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with XOMA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Usersuresh45
- Userdd
- ContributorStocks Under-$10 Setting Up...
- Userconsidering
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest XOMA Headlines from TheStreet
- 5 High Growth Healthcare Stocks With Heavy Insider Buying 06.18.13 | 04:06 pm
- XOMA Initiates Pilot Trial Studying Gevokizumab In Patients With Pyoderma Gangrenosum 06.13.13 | 09:06 am
- XOMA Highlights Recent Achievements And Reports Financial Results For First Quarter 2013 05.08.13 | 04:05 pm
- XOMA To Present At Credit Suisse 2013 Antibody Day 05.06.13 | 02:05 pm
- XOMA To Announce First Quarter 2013 Financial Results And Host Webcast On May 8 04.25.13 | 08:04 am
- XOMA Announces Clinical Study Investigating Gevokizumab In Patients With Non-Infectious Anterior Scleritis Has Opened For Enrollment At The National Eye Institute 04.10.13 | 08:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- XOMA Appoints Tom Klein To Newly Created Position Of Chief Commercial Officer 03.18.13 | 01:03 pm
- EZChip: My Struggling Core Holding May See Better Days 03.16.13 | 07:03 am
Press Releases for XOMA
- CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility - PR Newswire 07.31.12 | 08:07 am
Partner Headlines for XOMA
- Positive Data on XOMA Candidate - Analyst Blog - Zacks 11.26.12 | 06:11 pm
- UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential - Benzinga 11.13.12 | 01:11 pm
- XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis - Benzinga 09.27.12 | 01:09 pm
- Orphan Status for XOMA's Candidate - Analyst Blog - NASDAQ 08.23.12 | 07:08 pm
- Loss at XOMA Wider Than Expected - Analyst Blog - Zacks 03.20.12 | 10:03 am
- Noteworthy Institutional 5% Ownership Filings Last Week - Seeking Alpha 03.19.12 | 09:03 am
- Xoma's New Plans Bring Hesitant Hope - Seeking Alpha 01.25.12 | 09:01 am
- XOMA Will Move Its Corporate Domicile to Delaware - Benzinga 12.30.11 | 04:12 pm
- XOMA CEO Engle Resigns - Benzinga 08.31.11 | 04:08 pm
- 15 Stocks Posting Big Jumps This Week - Seeking Alpha 06.30.11 | 08:06 am
